Is there a domestic version of Cabozantinib?

Cabozantinib is a multi-target tyrosine kinase inhibitor widely used to treat a variety of malignancies, including advanced renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), differentiated thyroid cancer (DTC), and pancreatic neuroendocrine tumors (pNET). Although cabozantinib has been widely used in many countries and regions around the world, the original drug of cabozantinib is not yet on the market in the Chinese market, which also makes domestic patients face certain obstacles in obtaining treatment. Since the original drug has not yet entered the market, there are currently no domestic generic versions to choose from.

The original drug cabozantinib was developed by the American companyExelixis. It is mainly used to treat a series of malignant tumors such as metastatic renal cancer, liver cancer, and thyroid cancer. Although the drug has been approved and marketed in some developed countries, such as the United States and Europe, in China, due to factors such as market approval procedures, price control, and related policies, the original drug of cabozantinib has not yet been officially launched. Meanwhile, in the absence of domestic generic versions, patients rely on imported drugs, which often increases the cost of treatment.

Cabozantinib regimens are commonly used in patients with advanced or metastatic renal cell carcinoma, hepatocellular carcinoma, thyroid cancer, and pancreatic neuroendocrine tumors, all of which have a growing need for treatment. However, with the rapid development of domestic drugs, generic drugs for cabozantinib may appear in the future, but they have not yet been approved.

Currently, in the Chinese market, the imported drug price of cabozantinib is relatively expensive, and it is not included in the medical insurance reimbursement list, causing many patients to face a high financial burden. Therefore, although the therapeutic effect of cabozantinib has been widely recognized, patients still face greater challenges in terms of affordability.

Keyword tags: Cabotinib, Cabozantinib, domestic drugs, renal cell carcinoma, hepatocellular carcinoma, thyroid cancer, pancreatic neuroendocrine tumors, generic drugs, imported drugs

Reference materials:https://go.drugbank.com/drugs/DB08875